Citations

Showing 10 of 108083 citations.

Cervical Lymphangioma in the Adult
Schefter, Robert P., Olsen, Kerry D., Gaffey, Thomas A.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 12, 2017 | Volume: 93 | Issue: 1 | Pages: 65-69

10.1177/019459988509300113 | PMID 3920626 Get It

Cervical lymphangioma is rare among adults. Thirty‐two patients with cervical lymphangioma were treated at the Mayo Clinic between 1950 and 1982. The records of these patients were reviewed to investigate the clinical and pathologic behavior of this lesion in persons more than 16 years of age. The lesions were seen in all decades of adult life and equally in men and women. Most lesions presented as a rapidly enlarging, asymptomatic mass. The anterior triangle of the neck was involved nearly as often as the posterior triangle, and right‐sided locations predominated (72%). Histopathologic differentiation of the lesions into simplex, cavernous, and cystic lymphangiomas was not helpful in predicting clinical behavior. Surgical excision is the treatment of choice. The lesions may intimately involve the carotid sheath or adjacent nerves. Recurrence in 21% of the 28 patients on whom follow‐up data were available mostly represented incomplete excision. Lymphangioma should be included in the differential diagnosis of a large asymptomatic neck mass of recent origin in the adult.
P OEMS syndrome: 2017 Update on diagnosis, risk stratification, and management
Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | July 12, 2017 | Volume: 92 | Issue: 8 | Pages: 814-829

10.1002/ajh.24802 | PMID 28699668 Get It

Abstract Disease Overview POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnoses are often delayed because the syndrome is rare and can be mistaken for other neurologic disorders, most commonly chronic inflammatory demyelinating polyradiculoneuropathy. POEMS syndrome should be distinguished from the Castleman disease variant of POEMS syndrome, which has no clonal PCD and typically little to no peripheral neuropathy but has several of the minor diagnostic criteria for POEMS syndrome. Diagnosis The diagnosis of POEMS syndrome is made with 3 of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. Risk Stratification Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. The number of clinical criteria is not prognostic, but the extent of the plasma cell disorder is. Those patients with an iliac crest bone marrow biopsy that does not reveal a plasma cell clone are candidates for local radiation therapy; those with a more extensive or disseminated clone will be candidates for systemic therapy Risk‐Adapted Therapy For those patients with a dominant sclerotic plasmacytoma, first‐line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement and for those who have progression of their disease 3–6 months after completing radiation therapy should receive systemic therapy. Corticosteroids are temporizing, but alkylators are the mainstay of treatment, either in the form of low‐dose conventional therapy or high dose with stem cell transplantation. Lenalidomide shows promise with manageable toxicity. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. The benefit of anti‐VEGF antibodies is conflicting. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.
Idarucizumab (Praxbind) for Reversal of Pradaxa Prior to Emergent Repair of Contained Ruptured Transverse Arch Aneurysm
Belli, ErolVahit, Lee, Teng, Belli, Erol Vahit, Belli, Erol, Lee, Teng C.

Mayo Clinic

Annals of Cardiac Anaesthesia | July 12, 2017 | Volume: 20 | Issue: 3 | Pages: 369-371

10.4103/0971-9784.210426 | PMID 28701610 Get It

Idarucizumab before cardiopulmonary bypass was used for the reversal of dabigatran during an emergent frozen elephant trunk repair of a transverse arch aneurysm. Reversal was successful and minimal not massive transfusion was required with no abnormal sequelae seen with use before cardiopulmonary bypass.
High‐resolution anorectal manometry: An expensive hobby or worth every penny?
Basilisco, Guido , Bharucha, Adil E. , Bharucha, A E , Basilisco, Guido

Mayo Clinic

Neurogastroenterology & Motility | July 12, 2017 | Volume: 29 | Issue: 8 | Pages: No page available

10.1111/nmo.13125 | PMID 28699318 Get It

AbstractIntroduced approximately 10 years ago, high‐resolution manometry catheters have fostered interest in anorectal manometry. This review, which accompanies two articles in this issue of Neurogastroenterology and Motility, reviews the methods, clinical indications, utility, and pitfalls of anorectal manometry and revisits the American Gastroenterological Association (AGA) Medical Position Statement on Anorectal Testing Techniques, which was last published in 1999. High‐resolution manometry provides a refined assessment of the anorectal pressure profile, obviates the need for station pull‐through maneuvers, and minimizes movement artifacts. In selected cases, this refined assessment may be useful for identifying structural abnormalities or anal weakness. However, many manometry patterns that were previously regarded as abnormal are also observed in a majority of healthy patients, which substantially limits the utility of manometry for identifying defecatory disorders. It is our impression that most conclusions of the AGA medical position statement from 1999 remain valid today. High‐resolution techniques have not substantially affected the number of publications on or management of anorectal disorders. The ongoing efforts of an international working group to standardize techniques for anorectal manometry are welcome. Although high‐resolution manometry is more than an expensive hobby, improvements in catheter design and further research to rigorously define and evaluate these techniques are necessary to determine if they are worth every penny.
A monocyte‐TNF‐endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade
Solovey, Anna, Somani, Arif , Belcher, John D. , Milbauer, Liming , Vincent, Lucile , Pawliński, Rafał , Nath, Karl A. , Kelm, Robert J. , O’Sullivan, M. Gerard , Gupta, Kalpna , Vercellotti, Gregory M. , Hebbel, Robert P. , O’Sullivan, M. Gerard , Gupta, Kalpna , Hebbel, Robert P , Mackman, Nigel , O'Sullivan, M Gerard

Mayo Clinic

American Journal of Hematology | July 12, 2017 | Volume: 92 | Issue: 11 | Pages: 1119-1130

10.1002/ajh.24856 | PMID 28699284 Get It

AbstractElaboration of tumor necrosis factor (TNF) is a very early event in development of ischemia/reperfusion injury pathophysiology. Therefore, TNF may be a prominent mediator of endothelial cell and vascular wall dysfunction in sickle cell anemia, a hypothesis we addressed using NY1DD, S+SAntilles, and SS‐BERK sickle transgenic mice. Transfusion experiments revealed participation of abnormally activated blood monocytes exerting an endothelial activating effect, dependent upon Egr‐1 in both vessel wall and blood cells, and upon NFκB(p50) in a blood cell only. Involvement of TNF was identified by beneficial impact from TNF blockers, etanercept and infliximab, with less benefit from an IL‐1 blocker, anakinra. In therapeutic studies, etanercept ameliorated multiple disturbances of the murine sickle condition: monocyte activation, blood biomarkers of inflammation, low platelet count and Hb, vascular stasis triggered by hypoxia/reoxygenation (but not if triggered by hemin infusion), tissue production of neuro‐inflammatory mediators, endothelial activation (monitored by tissue factor and VCAM‐1 expression), histopathologic liver injury, and three surrogate markers of pulmonary hypertension (perivascular inflammatory aggregates, arteriolar muscularization, and right ventricular mean systolic pressure). In aggregate, these studies identify a prominent—and possibly dominant—role for an abnormal monocyte‐TNF‐endothelial activation axis in the sickle context. Its presence, plus the many benefits of etanercept observed here, argue that pilot testing of TNF blockade should be considered for human sickle cell anemia, a challenging but achievable translational research goal.
POEMS syndrome: An elusive diagnosis
Abeykoon, Jithma P. , Gonsalves, Wilson I. , Oliveira, Jennifer L. , Kapoor, Prashant , Herrick, Jennifer L. , Oliveira, Jennifer, Gonsalves, Wilson

Mayo Clinic

American Journal of Hematology | July 12, 2017 | Volume: 92 | Issue: 11 | Pages: 1269-1270

10.1002/ajh.24845 | PMID 28699264 Get It

Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma
Witzig, Thomas E. , Zinzani, Pier Luigi , Tuscano, Joseph M. , Drach, Johannes, Ramchandren, Radhakrishnan , Beşışık, Sevgi Kalayoğlu , Takeshita, Kenichi , Bravo, Marie‐Laure Casadebaig, Zhang, Lei , Witzig, T.E. , Habermann, Thomas M. , Fu, Tommy , Goy, Andre Henri , Zinzani, Pier Luigi

Mayo Clinic

American Journal of Hematology | July 12, 2017 | Volume: 92 | Issue: 10 | Pages: No page available

10.1002/ajh.24854 | PMID 28699256 Get It

AbstractMantle cell lymphoma (MCL) is a type of non‐Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post‐bortezomib). The purpose of this report is to provide longer follow‐up on the MCL‐001 study (follow‐ups were 6.8 [NHL‐002], 7.6 [NHL‐003], and 52.2 [MCL‐001] months). The 206 relapsed MCL patients treated with single‐agent lenalidomide (25 mg/day PO, days 1 to 21 every 28‐days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow‐up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%‐29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single‐agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib.
Evaluation of visual and computer‐based CT analysis for the identification of functional patterns of obstruction and restriction in hypersensitivity pneumonitis
Jacob, Joseph , Bartholmai, Brian J. , Brun, Anne‐Laure , Egashira, Ryoko , Rajagopalan, Srinivasan , Karwoski, Ronald A., Kokosi, Maria , Hansell, David M., Wells, Athol U. , Karwoski, Ronald, Kouranos, Vasileios , Bartholmai, Brian J , Egashira, Ryoko

Mayo Clinic

Respirology | July 12, 2017 | Volume: 22 | Issue: 8 | Pages: 1585-1591

10.1111/resp.13122 | PMID 28699237 Get It

ABSTRACTBackground and objectiveTo determine whether computer‐based quantification (CALIPER software) is superior to visual computed tomography (CT) scoring in the identification of CT patterns indicative of restrictive and obstructive functional indices in hypersensitivity pneumonitis (HP).MethodsA total of 135 consecutive HP patients had CT parenchymal patterns evaluated quantitatively by both visual scoring and CALIPER. Results were evaluated against: forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity for carbon monoxide (DLCO) and a composite physiological index (CPI) to identify which CT scoring method better correlated with functional indices.ResultsCALIPER‐derived scores of total interstitial lung disease extent correlated more strongly than visual scores: FVC (CALIPER R = 0.73, visual R = 0.51); DLCO (CALIPER R = 0.61, visual R = 0.48); and CPI (CALIPER R = 0·70, visual R = 0·55). The CT variable that correlated most strongly with restrictive functional indices was CALIPER pulmonary vessel volume (PVV): FVC R = 0.75, DLCO R = 0.68 and CPI R = 0.76.Ground‐glass opacity quantified by CALIPER alone demonstrated strong associations with restrictive functional indices: CALIPER FVC R = 0.65; DLCO R = 0.59; CPI R = 0.64; and visual = not significant. Decreased attenuation lung quantified by CALIPER was a better morphological measure of obstructive lung disease than equivalent visual scores as judged by relationships with TLC (CALIPER R = 0.63 and visual R = 0.12). All results were maintained on multivariate analysis.ConclusionCALIPER improved on visual scoring in HP as judged by restrictive and obstructive functional correlations. Decreased attenuation regions of the lung quantified by CALIPER demonstrated better linkages to obstructive lung physiology than visually quantified CT scores. A novel CALIPER variable, the PVV, demonstrated the strongest linkages with restrictive functional indices and could represent a new automated index of disease severity in HP.
A Variety of Rectourethral Fistulas: Experiences with 20 Cases
Culp, Ormond S., Calhoon, Harold W., Hw, Calhoon

Mayo Clinic

Journal of Urology | July 11, 2017 | Volume: 91 | Issue: 5 | Pages: 560-571

10.1016/s0022-5347(17)64171-5 | PMID 14154543 Get It

Ureterocele: Clinical Appraisal of 176 Cases
Thompson, Gershom J., Kelalis, Panayotis P.

Mayo Clinic

Journal of Urology | July 11, 2017 | Volume: 91 | Issue: 5 | Pages: 488-492

10.1016/s0022-5347(17)64157-0 | PMID 14154530 Get It